Oryon Cell Therapies
PrivateLast Round
Series A
Mar 23, 2026
Total Funding Raised
$42M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Oryon Cell Therapies operates in Healthcare & Life Sciences and is based in Belmont, Massachusetts. Its latest recorded funding round was a Series A round in March 2026.
Oryon Cell Therapies is a biotechnology company that develops autologous cell therapies for neurodegenerative disorders, with an initial focus on Parkinson's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oryon Cell Therapies Comparables
Compare Oryon Cell Therapies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aspen Neuroscience | 88% | |
| Shanghai UniXell Biotechnology | 88% | |
| Kenai Therapeutics | 86% |
For institutional investors. Book with your work email.
Oryon Cell Therapies Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Oryon Cell Therapies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Byers Capital | Series A |
| Neuro.VC | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 17, 2026
Grew 100% QoQ, from 3 to 6 employees.
- Sep 12, 2026
Monthly visitors increased 125% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresAug 27, 2026
Oryon Cell Therapies, Inc. appoints Kenny Choi, Ph.D., as Chief Technical Officer on Aug 27th '26 in Massachusetts to lead technical operations and CMC strategy.
- hiresAug 27, 2026
On Aug 27th '26, Oryon Cell Therapies, Inc. appoints Kenny Choi, Ph.D. as Chief Technical Officer to lead technical operations and Chemistry, Manufacturing, and Controls strategy, including transferring manufacturing of its autologous iPSC-derived dopaminergic neuron therapy from Mass General Brigham to its own facilities.
For institutional investors. Book with your work email.
Oryon Cell Therapies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Oryon Cell Therapies's valuation, stock price, and market status.
Is Oryon Cell Therapies a public or private company?
Oryon Cell Therapies is a private company.
What is the current stock price of Oryon Cell Therapies?
Oryon Cell Therapies is a private company, so its shares have no public market price. Caplight tracks Oryon Cell Therapies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Oryon Cell Therapies worth (valuation)?
Valuation information for Oryon Cell Therapies is not publicly available.
Can I buy Oryon Cell Therapies stock?
Oryon Cell Therapies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Oryon Cell Therapies's last funding round?
Oryon Cell Therapies's most recent funding round was Series A on March 23, 2026.
Who are the main investors in Oryon Cell Therapies?
Key investors in Oryon Cell Therapies include Byers Capital, Neuro.VC.
Will Oryon Cell Therapies IPO soon?
No public IPO plans have been announced for Oryon Cell Therapies.
How can I track Oryon Cell Therapies secondary market activity?
Caplight tracks bids, offers, and trades in Oryon Cell Therapies's shares on secondary markets.